Table 2.
Modeling of Potential Association of VEGF with NG
| Model | ||||||
|---|---|---|---|---|---|---|
| 1 | P | 2 | P | 3 | P | |
| Beta (se) | Beta (se) | Beta (se) | ||||
| VEGF | 538.9 (135) | <0.001 | 862(126) | <0.001 | 948 (124) | < 0.001 |
| Age, y | −7(2.2) | 0.002 | −7.4 (2.2) | < 0.001 | ||
| Gender | 156.9(31.7) | <0.001 | 159 (31) | < 0.001 | ||
| Education, y | 1.2(5.1) | 0.8 | 0.9 (5) | 0.85 | ||
| APOE4 (+) vs (-) | 129.3(31) | <0.001 | 67 (34) | 0.048 | ||
| MCI vs control | 141.4(36) | <0.001 | 95 (37) | 0.01 | ||
| AD vs control | 190(44.5) | <0.001 | 131 (45) | 0.004 | ||
| Aβ+ status | 167 (39) | < 0.001 | ||||
Notes: Linear regression models were applied to investigate the association of CSF NG levels with other variables. Model 1 was unadjusted; model 2 was adjusted for age, gender, education, APOE4 status and diagnosis; and model 3 was additionally adjusted for Aβ42. Beta is unstandardized beta.
Abbreviations: VEGF, vascular endothelial growth factor; NG, neurogranin; MCI, mild cognitive impairment; AD, Alzheimer’s disease; Aβ42, β-amyloid 42; T-tau, total tau; se, standard error.